Interest of Antiplatelet Drug Testing after an Acute XXXX .

@entity1 @entity32 @entity64 @entity6 @entity1423 @entity1397 @entity117 @entity385
BACKGROUND: @entity64 occurrence despite chronic antiplatelet drug (APD) treatment is frequent. We aimed at evaluating the relevance of @entity1423 testing in the identification of @entity64 etiology in this context. METHODS: @entity1 admitted for a suspected acute @entity385 , while under APD ( @entity117 and/or @entity1397 ), were prospectively included. The efficacy of the APD was evaluated using a Multiplate    assay. Resistance was confirmed using light transmission aggregometry. A standardized diagnostic work-up was performed to identify @entity64 mechanism according to the TOAST and the ASCO classifications. We evaluated the influence of APD functional status on @entity64 severity and identified potential determinants of resistance. RESULTS: APD resistance was observed in 53 of the 287 @entity1 (18.5%). No difference in @entity64 mechanism depending on APD efficacy was observed. @entity1 sensitive to APD had less severe @entity64 severity (mean National Institutes of Health @entity64 Scale 3.9    5.6 vs. 7.2    6.8; p < 0.01). Main determinants for APD resistance were a worse control of the @entity6 and higher baseline levels of @entity32 (mean CRP 26.4    56.0 vs. 9.3    21.0; p < 0.01). CONCLUSIONS: Platelet function testing does not provide orientation concerning @entity64 mechanism in @entity1 who were previously on APDs. However, the high frequency of APD resistance and its association with @entity32 and @entity64 severity are confirmed.
